Who Paid My Doc
Kenneth Graham
Pediatrics Kalispell, MT Medical Doctor
NPI 1720069875 CMS profile 1180964
1273 Burns Way, Kalispell, MT 59901
General payments
$150
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kenneth Graham of Kalispell, MT is reported in the CMS Open Payments database as having received $150 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 44th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $50 | 1 | |
| 2024 | General | $100 | 1 |
Beside peers
- Kenneth Graham
- Pediatrics median
- Middle half of Pediatrics
- National median
In program year 2025, general payments to Kenneth Graham were reported at $50. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.
Show as a table
| Year | Kenneth Graham | Pediatrics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $86 | $31–$183 | $163 |
| 2020 | $0 | $49 | $22–$110 | $114 |
| 2021 | $0 | $68 | $27–$158 | $132 |
| 2022 | $0 | $77 | $30–$173 | $149 |
| 2023 | $0 | $88 | $33–$190 | $160 |
| 2024 | $100 | $94 | $34–$206 | $164 |
| 2025 | $50 | $97 | $37–$210 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
9,153
Drug cost
$1,950,330
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Arexvy Rsvpref3 Antigen/As01e/Pf | Brand | 2,999 | $854,658 | |
| Shingrix Varicella-Zoster Ge/As01b/Pf | Brand | 3,681 | $735,046 | |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | Brand | 886 | $247,706 | |
| Boostrix Tdap Diphth,pertuss(Acell),tet Vac | Brand | 1,375 | $86,200 | |
| Twinrix Hepatitis A And B Vaccine/Pf | Brand | 188 | $25,265 | |
| Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf | Brand | 24 | $1,455 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatrics in Montana
Related records
Pediatrics in Montana
Practitioners in the same specialty and state, ranked by reported value.
All Pediatrics
Everyone recorded under this specialty, nationwide.
Doctors in Montana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.